posted
GenoMed's West Nile Virus Trial Endorsed by Emergency Medicine Authority 8/8/2006 ST. LOUIS, Aug 08, 2006 /PRNewswire-FirstCall via COMTEX News Network/ --
GenoMed (Pink Sheets: GMED), a Next Generation Disease Management company whose business is public health(TM), today announced the endorsement of its trial for West Nile virus encephalitis by an authority in Emergency Medicine, Dr. Neal Handly.
Dr. Handly is Associate Director of Research for the Department of Emergency Medicine at Drexel University College of Medicine and a Fellow of the American Academy of Emergency Medicine. Dr. Handly chairs the Academy's Subcommittee on Information Technology.
Dr. Handly said, "GenoMed's protocol is extremely exciting, since we're in the grip of another West Nile epidemic this summer without any known treatment. The Emergency Room is where these cases are seen first. It makes sense to have the ER be a partner in a clinical trial."
Dr. Handly continued, "Dr. Moskowitz uses safe medicines already familiar to every ER physician. What makes his approach appealing is the possibility that it may work for many viruses, including avian influenza and bioterrorist viral attacks. These last two scenarios are of special concern to the Emergency Medicine community."
About Dr. Handly
Dr. Neal Handly is an Assistant Professor in the Department of Emergency Medicine at Drexel University College of Medicine in Philadelphia, PA. He was consulted to create a state-of-the-art ER this summer in Beirut, Lebanon but has been prevented from doing so by the current hostilities.
About GenoMed
Since 2003, GenoMed has been using safe, FDA-approved, prescription-only blood pressure pills to treat West Nile virus encephalitis. So far, GenoMed has had an 86% treatment success rate (19 of 22 patients). This summer the Company extended its trial successfully to include horses. Anyone can download the WNV trial protocol from GenoMed's website, http://www.genomed.com , by clicking on the "West Nile trial" link. An email address is required for clinical follow-up.
Safe Harbor Statement
This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
SOURCE GenoMed, Inc.
Neal Handly, MD, +1-610-563-0664, nh28*drexel.edu , or David W. Moskowitz, MD, CEO, GenoMed, +1-314-983-9933, dwmoskowitz*genomed.com http://www.prnewswire.com Copyright (C) 2006 PR Newswire. All rights reserved.
posted
I bought this last week on th enews of the success they had curing horses with bird flu and today's news just adds to it. I've looked into the management of the company and they look solid. Would be nice to see this get the attention it deserves.
Blood Pressure Medication Fights West Nile in Horse
By Michelle DeGrand
TOOLS
Email this story to a friend Printer-friendly Version
LINKS
West Nile Trial
MARSING - More than 60 Idaho horses have tested positive for West Nile Virus, according to the Idaho Department of Health and Welfare. Now, some horse lovers are hanging their hopes on a new treatment that brings human medicine to the pasture.
"Come here Frog," says Jackie Dines, as she calls a bay colored horse to the edge of a pen built in the shade of her backyard. The horse named "Frog" was diagnosed with West Nile in late July, but Dines says he's looking a little less green every day.
She says that's thanks to a new treatment using human blood pressure medication, that he's been taking for about ten days. She's so willing to put faith in the treatment because she's already lost one horse to the disease this year.
"The first one we did exactly as the vet told us, and we lost him," she said. After that, a friend told Dines about an out-of-state M.D. with services online who uses blood pressure medication to treat West Nile.
St. Louis-based company, Genomed's Dr. David Moskowitz, says whether it's a severely affected horse or human, the victim's brain is flooded with too many white blood cells because their body overreacts to the virus. The blood pressure medication suppresses that immune system response, and stops the body from essentially destroying itself.
So far, they've treated 22 people, but "Frog" was the first horse.
"We're running 86 percent treatment success rate in people, a hundred percent in horses, but we're only one for one in horses," said Dr. Moskowitz in a phone interview with CBS 2 News. They've also treated birds. Moskowitz says the possibilities for these blood pressure meds could reach all the way to treating bio terror diseases like Ebola and even the common cold.
But although Dines' first horse didn't survive the illness, veterinarians are happy with the treatments available to horses now. And in Idaho this year, vets have plenty of test subjects.
In Nampa, Dr. Joe Rumsey has been inundated with West Nile horse cases; four times the number he saw last year.
"I'm going to say we've gotten, I don't know, 15 maybe 20 positive cases so far this year," Dr. Rumsey said as he doctored a white Arabian that tested positive for West Nile. The horse had trouble walking straight, and almost constant facial ticks that Rumsey says are common symptoms for West Nile.
But he says treatment has gotten better using what's called Hyper Immune Plasma. It's plasma from horses who've been vaccinated 35 to a hundred times for West Nile. An east coast company manufactures the plasma, but last year it was so hard to get, Rumsey over-vaccinated his own horses and used them to get plasma for sick horses.
It's worked for every horse he's treated, although some were euthanized because the owners couldn't afford to treat them, which can cost more than a thousand dollars. He says horses rarely recover a hundred percent, and often still have coordination problems, preventing them from many athletic tasks like racing. But he knows it works and as yet, he's not ready to endorse Moskowitz' treatment.
"Right now I'm going to have to stick with the plasma," he said, "I honestly don't see enough evidence that this stuff is going to work in the most basic sense."
But Dines stands by the method, as long as "Frog" is still standing.
"He's not out of the woods yet but, I mean, he's got a fighting chance now which I don't think he would have had before," Dines said.
Rumsey says the best protection is vaccination for horses, which costs only 22 dollars a dose for a two shot series a month apart. He says most horses he sees have never been vaccinated. Some horses vaccinated last year but not this year also went to his clinic with the disease, but he says their symptoms weren't as severe as those who'd never been vaccinated. He hasn't seen any horses who are up-to-date on their vaccinations contract West Nile.
Genco is still accepting human cases for their clinical trial of blood pressure medication in fighting West Nile Virus. Click the link at the top of this page to learn more.
posted
GenoMed, Inc. (Pink Sheets: GMED), a Next Generation Disease Management (DM) company whose business is public health(TM), announced today that it has obtained clearance, through their Indian distributor Sumit Biosciences Pvt Ltd, from the Indian Government to market its Next Generation DM(TM) product in India.
The cost is under US $150 per patient per year. Since the per capita income in India is around US $600 a year, GenoMed's Next Generation DM(TM) service is well within the reach of the average Indian citizen.
Sumit Biosciences Pvt Ltd is currently enlisting physicians at the King Edward Memorial Hospital in Mumbai to offer GenoMed's protocols to their patients. Mumbai, formerly called Bombay, is the fourth largest city in the world, with 12 million inhabitants.
Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, said, "The US and Europe have been completely uninterested in our published methods for preventing kidney dialysis and slowing down emphysema. The $25 billion a year that the US spends on dialysis may actually serve as a perverse financial disincentive not to eliminate the industry. India spends nothing on dialysis, so nobody there has a financial stake in preserving the dialysis industry."
Added Dr. Moskowitz, "It's as if the Directors of the TB sanitaria in the US ignored streptomycin in 1950 to save their jobs. It's a shame that the taxpayers of the US and Europe are paying for genomics-based medicine, but citizens of developing countries like India are the only ones using it."
GenoMed is currently trading at $0.017 on volume of 608,700 shares.
About GenoMed
Since 2003, GenoMed has been using safe, FDA-approved, prescription-only blood pressure pills to treat West Nile virus encephalitis. So far, GenoMed has had an 86% treatment success rate (19 of 22 patients). This summer the Company extended its trial successfully to include horses. Anyone can download the WNV trial protocol from GenoMed's website, http://www.genomed.com , by clicking on the "West Nile trial" link. An email address is required for clinical follow-up.
-------------------- "Reality is the leading cause of stress amongst those in touch with it."
IP: Logged |
Topic Closed
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
